227 related articles for article (PubMed ID: 32779487)
1. Drugging all RAS isoforms with one pocket.
Kessler D; Bergner A; Böttcher J; Fischer G; Döbel S; Hinkel M; Müllauer B; Weiss-Puxbaum A; McConnell DB
Future Med Chem; 2020 Nov; 12(21):1911-1923. PubMed ID: 32779487
[TBL] [Abstract][Full Text] [Related]
2. Drugging the Undruggable: Advances on RAS Targeting in Cancer.
Molina-Arcas M; Samani A; Downward J
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34200676
[TBL] [Abstract][Full Text] [Related]
3. Drugging an undruggable pocket on KRAS.
Kessler D; Gmachl M; Mantoulidis A; Martin LJ; Zoephel A; Mayer M; Gollner A; Covini D; Fischer S; Gerstberger T; Gmaschitz T; Goodwin C; Greb P; Häring D; Hela W; Hoffmann J; Karolyi-Oezguer J; Knesl P; Kornigg S; Koegl M; Kousek R; Lamarre L; Moser F; Munico-Martinez S; Peinsipp C; Phan J; Rinnenthal J; Sai J; Salamon C; Scherbantin Y; Schipany K; Schnitzer R; Schrenk A; Sharps B; Siszler G; Sun Q; Waterson A; Wolkerstorfer B; Zeeb M; Pearson M; Fesik SW; McConnell DB
Proc Natl Acad Sci U S A; 2019 Aug; 116(32):15823-15829. PubMed ID: 31332011
[TBL] [Abstract][Full Text] [Related]
4. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
[TBL] [Abstract][Full Text] [Related]
5. Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.
Coley AB; Ward A; Keeton AB; Chen X; Maxuitenko Y; Prakash A; Li F; Foote JB; Buchsbaum DJ; Piazza GA
Adv Cancer Res; 2022; 153():131-168. PubMed ID: 35101229
[TBL] [Abstract][Full Text] [Related]
6. RAS-targeted therapies: is the undruggable drugged?
Moore AR; Rosenberg SC; McCormick F; Malek S
Nat Rev Drug Discov; 2020 Aug; 19(8):533-552. PubMed ID: 32528145
[TBL] [Abstract][Full Text] [Related]
7. Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion.
Quinlan MP; Quatela SE; Philips MR; Settleman J
Mol Cell Biol; 2008 Apr; 28(8):2659-74. PubMed ID: 18268007
[TBL] [Abstract][Full Text] [Related]
8. Progress on Covalent Inhibition of KRAS(G12C).
Westover KD; Jänne PA; Gray NS
Cancer Discov; 2016 Mar; 6(3):233-4. PubMed ID: 26951837
[TBL] [Abstract][Full Text] [Related]
9. Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS
Bröker J; Waterson AG; Smethurst C; Kessler D; Böttcher J; Mayer M; Gmaschitz G; Phan J; Little A; Abbott JR; Sun Q; Gmachl M; Rudolph D; Arnhof H; Rumpel K; Savarese F; Gerstberger T; Mischerikow N; Treu M; Herdeis L; Wunberg T; Gollner A; Weinstabl H; Mantoulidis A; Krämer O; McConnell DB; W Fesik S
J Med Chem; 2022 Nov; 65(21):14614-14629. PubMed ID: 36300829
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
Tang D; Kroemer G; Kang R
Mol Cancer; 2021 Oct; 20(1):128. PubMed ID: 34607583
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Nonfunctional Ras.
Nussinov R; Jang H; Gursoy A; Keskin O; Gaponenko V
Cell Chem Biol; 2021 Feb; 28(2):121-133. PubMed ID: 33440168
[TBL] [Abstract][Full Text] [Related]
12. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.
Zeng M; Lu J; Li L; Feru F; Quan C; Gero TW; Ficarro SB; Xiong Y; Ambrogio C; Paranal RM; Catalano M; Shao J; Wong KK; Marto JA; Fischer ES; Jänne PA; Scott DA; Westover KD; Gray NS
Cell Chem Biol; 2017 Aug; 24(8):1005-1016.e3. PubMed ID: 28781124
[TBL] [Abstract][Full Text] [Related]
13. Drugging K-Ras
Ni D; Li X; He X; Zhang H; Zhang J; Lu S
Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
[TBL] [Abstract][Full Text] [Related]
14. The reactivity-driven biochemical mechanism of covalent KRAS
Hansen R; Peters U; Babbar A; Chen Y; Feng J; Janes MR; Li LS; Ren P; Liu Y; Zarrinkar PP
Nat Struct Mol Biol; 2018 Jun; 25(6):454-462. PubMed ID: 29760531
[TBL] [Abstract][Full Text] [Related]
15. Mutant-Specific Targeting of Ras G12C Activity by Covalently Reacting Small Molecules.
Goody RS; Müller MP; Rauh D
Cell Chem Biol; 2019 Oct; 26(10):1338-1348. PubMed ID: 31378709
[TBL] [Abstract][Full Text] [Related]
16. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
Nyíri K; Koppány G; Vértessy BG
Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
[TBL] [Abstract][Full Text] [Related]
17. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
18. Probing RAS Function with Monobodies.
Khan I; O'Bryan JP
Methods Mol Biol; 2021; 2262():281-302. PubMed ID: 33977484
[TBL] [Abstract][Full Text] [Related]
19. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
Patricelli MP; Janes MR; Li LS; Hansen R; Peters U; Kessler LV; Chen Y; Kucharski JM; Feng J; Ely T; Chen JH; Firdaus SJ; Babbar A; Ren P; Liu Y
Cancer Discov; 2016 Mar; 6(3):316-29. PubMed ID: 26739882
[TBL] [Abstract][Full Text] [Related]
20. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
Nussinov R; Zhang M; Tsai CJ; Jang H
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
